| Overview |
| bsm-61275r-cy3-100ul |
| BPI Recombinant Monoclonal Antibody, Cy3 Conjugated |
| WB, FCM, IF(ICC) |
| Human |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human BPI |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 671 |
| P17213 |
| Cytoplasm, Secreted, Cell membrane |
| rBPI; BPIFD1; CAP 57; BPI; Bactericidal permeability-increasing protein. |
| The cytotoxic action of BPI is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, this activity is inhibited by LPS from P.aeruginosa. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz